These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3351524)

  • 1. Aggravation of Parkinson's disease by cinnarizine.
    Fernandez Pardal M; Fernandez Pardal J; Micheli F
    J Neurol Neurosurg Psychiatry; 1988 Jan; 51(1):158-9. PubMed ID: 3351524
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced parkinsonism: cinnarizine and flunarizine are potent uncouplers of the vacuolar H+-ATPase in catecholamine storage vesicles.
    Terland O; Flatmark T
    Neuropharmacology; 1999 Jun; 38(6):879-82. PubMed ID: 10465691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible pharmacokinetic and pharmacodynamic factors affecting parkinsonism inducement by cinnarizine and flunarizine.
    Kariya S; Isozaki S; Masubuchi Y; Suzuki T; Narimatsu S
    Biochem Pharmacol; 1995 Nov; 50(10):1645-50. PubMed ID: 7503767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinergic stimulation of the caudate nucleus in rats: a model of Parkinson's disease.
    Matthews RT; Chiou CY
    Neuropharmacology; 1978 Oct; 17(10):879-82. PubMed ID: 745684
    [No Abstract]   [Full Text] [Related]  

  • 5. Flunarizine and cinnarizine-induced parkinsonism: a historical and clinical analysis.
    Teive HA; Troiano AR; Germiniani FM; Werneck LC
    Parkinsonism Relat Disord; 2004 Jun; 10(4):243-5. PubMed ID: 15120099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.
    Graybiel AM; Moratalla R; Quinn B; DeLanney LE; Irwin I; Langston JW
    Adv Neurol; 1993; 60():34-9. PubMed ID: 8420148
    [No Abstract]   [Full Text] [Related]  

  • 7. Flunarizine- and cinnarizine-induced extrapyramidal reactions.
    Micheli F; Pardal MF; Gatto M; Torres M; Paradiso G; Parera IC; Giannaula R
    Neurology; 1987 May; 37(5):881-4. PubMed ID: 3574697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinsonism, tremor, and depression induced by cinnarizine and flunarizine.
    Capellà D; Laporte JR; Castel JM; Tristán C; Cos A; Morales-Olivas FJ
    BMJ; 1988 Sep; 297(6650):722-3. PubMed ID: 3147743
    [No Abstract]   [Full Text] [Related]  

  • 9. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism.
    Veitch K; Hue L
    Mol Pharmacol; 1994 Jan; 45(1):158-63. PubMed ID: 8302275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Movement disorders and depression due to flunarizine and cinnarizine.
    Micheli FE; Pardal MM; Giannaula R; Gatto M; Parera I; Paradiso G; Torres M; Pikielny R; Pardal J
    Mov Disord; 1989; 4(2):139-46. PubMed ID: 2733706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 12. [Parkinson syndrome after administration of acetylcholine into the caudate nuclei].
    Kryzhanovskiĭ GN; Atadzhanov MA; Voronina TA; Nerobkova LN
    Biull Eksp Biol Med; 1989 May; 107(5):522-5. PubMed ID: 2736276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
    Russ H; Henning K; Eckhardt H; Przuntek H
    Arzneimittelforschung; 1985; 35(2):481-2. PubMed ID: 2581589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN; Thakar JH; Grimes JD
    Adv Neurol; 1990; 53():219-23. PubMed ID: 2239461
    [No Abstract]   [Full Text] [Related]  

  • 15. Anticonvulsive properties of cinnarizine and flunarizine in rats and mice.
    Desmedt LK; Niemegeers CJ; Janssen PA
    Arzneimittelforschung; 1975 Sep; 25(9):1408-13. PubMed ID: 1242663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism.
    Negrotti A; Calzetti S
    Mov Disord; 1997 Jan; 12(1):107-10. PubMed ID: 8990063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium-entry blockers-induced parkinsonism: possible role of inherited susceptibility.
    Negrotti A; Calzetti S; Sasso E
    Neurotoxicology; 1992; 13(1):261-4. PubMed ID: 1508427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of new pharmacological approaches in Parkinson's disease.
    Carlsson A
    Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631
    [No Abstract]   [Full Text] [Related]  

  • 19. Striatal dopamine depletion, dopamine receptor stimulation, and GABA metabolism: implications for the therapy of Parkinson's disease.
    Bennett JP
    Ann Neurol; 1986 Feb; 19(2):194-7. PubMed ID: 3083762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iatrogenic parkinsonism: the role of flunarizine and cinnarizine.
    Miguel R; Correia AS; Bugalho P
    J Parkinsons Dis; 2014; 4(4):645-9. PubMed ID: 25125483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.